

Massimo Serra

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7536005/massimo-serra-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

116
papers

5,518
citations

44
h-index

71
g-index

117
ext. papers

6,167
ext. citations

6.6
avg, IF

5.04
L-index

#	Paper	IF	Citations
116	Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. <i>New England Journal of Medicine</i> , 1995 , 333, 1380-5	59.2	331
115	Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. <i>Clinical Cancer Research</i> , 2011 , 17, 2110-9	12.9	271
114	Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. <i>Cancer Research</i> , 2005 , 65, 3868-76	10.1	252
113	Modulation of the osteosarcoma expression phenotype by microRNAs. <i>PLoS ONE</i> , 2012 , 7, e48086	3.7	226
112	Genome-wide association study identifies two susceptibility loci for osteosarcoma. <i>Nature Genetics</i> , 2013 , 45, 799-803	36.3	156
111	An update on chemotherapy for osteosarcoma. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2727-36	4	147
110	Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. <i>Laboratory Investigation</i> , 2011 , 91, 1195-205	5.9	130
109	Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. <i>Genes Chromosomes and Cancer</i> , 2010 , 49, 40-51	5	124
108	miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. <i>Journal of Pathology</i> , 2012 , 226, 796-805	9.4	113
107	Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. <i>European Journal of Cancer</i> , 2005 , 41, 1349-61	7.5	109
106	Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. <i>Cancer Research</i> , 2008 , 68, 6661-8	10.1	96
105	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. <i>Cancer Gene Therapy</i> , 2002 , 9, 296-307	5.4	95
104	Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2209-16	2.2	93
103	The expression of ccn3(nov) gene in musculoskeletal tumors. <i>American Journal of Pathology</i> , 2002 , 160, 849-59	5.8	93
102	Gene amplifications in osteosarcoma-CGH microarray analysis. <i>Genes Chromosomes and Cancer</i> , 2005 , 42, 158-63	5	91
101	Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor. <i>Human Pathology</i> , 1996 , 27, 408-16	3.7	87
100	Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. <i>Journal of Clinical Oncology</i> , 2003 , 21, 536-42	2.2	86

99	Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. <i>International Journal of Cancer</i> , 2002 , 101, 11-6	7.5	86
98	Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. <i>Clinical Cancer Research</i> , 2001 , 7, 1790-7	12.9	84
97	In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. <i>Oncogene</i> , 2005 , 24, 4349-61	9.2	83
96	Emerging drugs for high-grade osteosarcoma. <i>Expert Opinion on Emerging Drugs</i> , 2010 , 15, 615-34	3.7	81
95	Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma. <i>Clinical Cancer Research</i> , 2012 , 18, 432-41	12.9	80
94	Clinical relevance of Ki-67 expression in bone tumors. <i>Cancer</i> , 1995 , 75, 806-14	6.4	78
93	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014 , 23, 6616-33	5.6	77
92	Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. <i>PLoS ONE</i> , 2012 , 7, e48262	3.7	75
91	Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling. <i>Cancer Research</i> , 2007 , 67, 7675-85	10.1	73
90	A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma. <i>Cancer Discovery</i> , 2015 , 5, 920-31	24.4	71
89	Redundancy of autocrine loops in human osteosarcoma cells. <i>International Journal of Cancer</i> , 1999 , 80, 581-8	7.5	69
88	LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 2009 , 48, 679-93	5	68
87	Advances in emerging drugs for osteosarcoma. <i>Expert Opinion on Emerging Drugs</i> , 2015 , 20, 495-514	3.7	67
86	C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1952-60	2.2	65
85	Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells. <i>Cancer Immunology, Immunotherapy</i> , 2011 , 60, 575-86	7.4	64
84	The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. <i>American Journal of Pathology</i> , 2000 , 157, 2123-31	5.8	64
83	Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma. <i>Cancer Genetics and Cytogenetics</i> , 1998 , 100, 106-10		63
82	IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. <i>BMC Cancer</i> , 2013 , 13, 245	4.8	62

81	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. <i>JAMA Oncology</i> , 2020 , 6, 724-734	13.4	60
80	Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines. <i>Molecular BioSystems</i> , 2012 , 8, 994-1006		57
79	Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2640-2652	6.1	57
78	Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. <i>Clinical Cancer Research</i> , 2009 , 15, 3550-6	12.9	56
77	Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. <i>International Journal of Cancer</i> , 2004 , 108, 358-66	7.5	55
76	Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. <i>Cancer Genetics and Cytogenetics</i> , 2000 , 123, 128-32		55
75	Prognostic value of CCN3 in osteosarcoma. <i>Clinical Cancer Research</i> , 2008 , 14, 701-9	12.9	54
74	CD99 acts as an oncosuppressor in osteosarcoma. <i>Molecular Biology of the Cell</i> , 2006 , 17, 1910-21	3.5	50
73	Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21. <i>Oncogene</i> , 2002 , 21, 2261-9	9.2	50
72	Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy. <i>BMC Medical Genomics</i> , 2014 , 7, 4	3.7	43
71	Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival. <i>European Journal of Cancer</i> , 2011 , 47, 1258-66	7.5	43
70	Mechanisms of gene amplification and evidence of coamplification in drug-resistant human osteosarcoma cell lines. <i>Genes Chromosomes and Cancer</i> , 2009 , 48, 289-309	5	41
69	Genetic imbalances in 67 synovial sarcomas evaluated by comparative genomic hybridization. <i>Genes Chromosomes and Cancer</i> , 1998 , 23, 213-219	5	40
68	New model for bone resorption study in vitro: human osteoclast-like cells from giant cell tumors of bone. <i>Journal of Bone and Mineral Research</i> , 1994 , 9, 1013-20	6.3	37
67	Malignant fibrous histiocytoma of bone: analysis of genomic imbalances by comparative genomic hybridisation and C-MYC expression by immunohistochemistry. <i>European Journal of Cancer</i> , 2006 , 42, 1172-80	7.5	37
66	Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. <i>Annals of Oncology</i> , 2008 , 19, 1500-1508	10.3	36
65	Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. <i>Clinical Cancer Research</i> , 2002 , 8, 3893-903	12.9	36
64	Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1 can Overcome Drug Resistance in Osteosarcoma. <i>Current Cancer Drug Targets</i> , 2016 , 16, 261-74	2.8	35

63	H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 4881-9	8.3	35
62	Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. <i>European Journal of Cell Biology</i> , 2003 , 82, 483-93	6.1	34
61	Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma. <i>Cellular and Molecular Life Sciences</i> , 2019 , 76, 609-625	10.3	32
60	The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. <i>Oncogene</i> , 1999 , 18, 739-46	9.2	29
59	Evaluation of osteonectin as a diagnostic marker of osteogenic bone tumors. <i>Human Pathology</i> , 1992 , 23, 1326-31	3.7	28
58	mRNA expression profiles of primary high-grade central osteosarcoma are preserved in cell lines and xenografts. <i>BMC Medical Genomics</i> , 2011 , 4, 66	3.7	27
57	Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). <i>International Journal of Cancer</i> , 2010 , 126, 41-52	7.5	27
56	Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts. <i>Cancer Letters</i> , 2019 , 456, 29-39	9.9	26
55	Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. <i>Oncotarget</i> , 2016 , 7, 61970-61987	3.3	26
54	An update on emerging drugs in osteosarcoma: towards tailored therapies?. <i>Expert Opinion on Emerging Drugs</i> , 2019 , 24, 153-171	3.7	25
53	Establishment and characterization of a primitive neuroectodermal tumor of bone continuous cell line (LAP-35). <i>International Journal of Cell Cloning</i> , 1990 , 8, 409-24		24
52	Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance. <i>Investigational New Drugs</i> , 2014 , 32, 1167-80	4.3	22
51	Murine model for skeletal metastases of Ewing's sarcoma. <i>Journal of Orthopaedic Research</i> , 2000 , 18, 959-66	3.8	21
50	P-glycoprotein subcellular localization and cell morphotype in MDR1 gene-transfected human osteosarcoma cells. <i>Biology of the Cell</i> , 1999 , 91, 17-28	3.5	21
49	Functionalized Keratin as Nanotechnology-Based Drug Delivery System for the Pharmacological Treatment of Osteosarcoma. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	21
48	Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 1449-63	5.5	19
47	Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 291-306	5	19
46	Genetic analysis of fibrosarcoma of bone, a rare tumour entity closely related to osteosarcoma and malignant fibrous histiocytoma of bone. <i>European Journal of Cell Biology</i> , 2004 , 83, 483-91	6.1	19

45	Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. <i>International Journal of Cancer</i> , 2018 , 142, 1594-1601	7.5	19
44	May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. <i>International Journal of Oncology</i> , 2006 , 29, 1459-68	1	19
43	Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?. <i>Future Oncology</i> , 2017 , 13, 673-677	3.6	18
42	Cisplatin Resistance in Osteosarcoma: Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments. <i>Frontiers in Oncology</i> , 2020 , 10, 331	5.3	18
41	Targeting Glutathione-S Transferase Enzymes in Musculoskeletal Sarcomas: A Promising Therapeutic Strategy. <i>Analytical Cellular Pathology</i> , 2011 , 34, 131-145	3.4	18
40	Identification of EWS/FLI-1 transcripts in giant-cell tumor of bone. <i>International Journal of Cancer</i> , 2000 , 87, 328-35	7.5	18
39	Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells. <i>PLoS ONE</i> , 2016 , 11, e0166233	3.7	18
38	Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines. <i>Cancer Letters</i> , 2018 , 433, 18-32	9.9	17
37	Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients. <i>Pharmacogenomics</i> , 2016 , 17, 2097-2114	2.6	16
36	Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy. <i>Histopathology</i> , 2015 , 67, 338-47	7.3	15
35	Pre-treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin. <i>International Journal of Cancer</i> , 1994 , 58, 95-101	7.5	15
34	Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors. <i>Cells</i> , 2020 , 9,	7.9	14
33	Frequent deletion of CDKN2A and recurrent coamplification of KIT, PDGFRA, and KDR in fibrosarcoma of bone--an array comparative genomic hybridization study. <i>Genes Chromosomes and Cancer</i> , 2010 , 49, 132-43	5	14
32	ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma. <i>Cells</i> , 2020 , 9,	7.9	13
31	Copy number alterations and neoplasia-specific mutations in MELK, PDCD1LG2, TLN1, and PAX5 at 9p in different neoplasias. <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 579-88	5	13
30	Prognostic value of P-glycoprotein in high-grade osteosarcoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4858-60; author reply 4860-1	2.2	13
29	Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 245-257	5.5	12
28	Prognostic significance of nuclear accumulation of c-myc and mdm2 proteins in synovial sarcoma of the extremities. <i>Oncology</i> , 2000 , 58, 253-60	3.6	12

27	Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies. <i>Cancers</i> , 2021 , 13,	6.6	12
26	Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 1992 , 119, 121-6	4.9	11
25	An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. <i>BMC Cancer</i> , 2014 , 14, 137	4.8	10
24	Genetic testing for high-grade osteosarcoma: a guide for future tailored treatments?. <i>Expert Review of Molecular Diagnostics</i> , 2018 , 18, 947-961	3.8	9
23	Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 299-311	5.5	8
22	4-Demethoxy-3Sdeamino-3Saziridinyl-4Smethylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients. <i>European Journal of Cancer</i> , 2005 , 41, 2184-95	7.5	8
21	May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol 2006 , 29, 1459		8
20	Establishment and characterization of in vivo orthotopic bioluminescent xenograft models from human osteosarcoma cell lines in Swiss nude and NSG mice. <i>Cancer Medicine</i> , 2018 , 7, 665-676	4.8	7
19	Caveolins in the development and diseases of musculoskeletal system. <i>Cancer Letters</i> , 2009 , 284, 113-219.9		7
18	Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	6
17	P53 oncosuppressor influences selection of genomic imbalances in response to ionizing radiations in human osteosarcoma cell line SAOS-2. <i>International Journal of Radiation Biology</i> , 2008 , 84, 591-601	2.9	6
16	Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities. <i>Cytotechnology</i> , 1996 , 19, 253-6	2.2	5
15	Giant Cell Tumor of Bone: A Model for the in Vitro Human Osteoclast Characterization. <i>Tumori</i> , 1989 , 75, 389-395	1.7	5
14	Characterization of water-soluble esters of nitrobenzoxadiazole-based GSTP1-1 inhibitors for cancer treatment. <i>Biochemical Pharmacology</i> , 2020 , 178, 114060	6	4
13	Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
12	Ki-67 Antigen Retrieval in Formalin- or Ethanol-fixed, Paraffin-embedded Tissues: An Enhancement Method for Immunohistochemical Staining with Autoclave Treatment.. <i>Acta Histochemica Et Cytochemica</i> , 1997 , 30, 251-255	1.9	4
11	Genomic imbalances associated with secondary acute leukemias in Hodgkin lymphoma. <i>Oncology Reports</i> , 2007 , 18, 1427-34	3.5	4
10	Long-Term Follow-up of a Randomized Study of Oral Etoposide versus Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse. <i>Sarcoma</i> , 2020 , 2020, 8260730	3.1	3

9	Polymorphisms of genes related to metotrexate response and toxicity in high-grade osteosarcoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 123	5.5	2
8	Impact of ABC Transporters in Osteosarcoma and Ewing's Sarcoma: Which Are Involved in Chemoresistance and Which Are Not?. <i>Cells</i> , 2021 , 10,	7.9	2
7	Retinoblastoma Susceptibility Gene Product Retrieval in Formalin-fixed, Paraffin-embedded Tissue: A Heating Method for Enhancing Immunohistochemical Staining.. <i>Acta Histochemica Et Cytochemica</i> , 1998 , 31, 193-196	1.9	1
6	Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells		1
5	miR-486-5p expression is regulated by DNA methylation in osteosarcoma.. <i>BMC Genomics</i> , 2022 , 23, 1424.5	4.5	1
4	Phase 2 study for nonmetastatic extremity high-grade osteosarcoma in pediatric and adolescent and young adult patients with a risk-adapted strategy based on ABCB1/P-glycoprotein expression: An Italian Sarcoma Group trial (ISG/OS-2).. <i>Cancer</i> , 2022 ,	6.4	1
3	Biology of Osteosarcomas 2020 , 213-215		
2	Prognostic Relevance of CCN3 in Bone Sarcomas 2010 , 223-243		
1	Biology of Osteosarcoma 2014 , 185-188		